Change - Announcement of Appointment::Appointment of Executive Director

Issuer & Securities

Issuer/ Manager
THOMSON MEDICAL GROUP LIMITED
Securities
THOMSON MED S$225M4.8%N220718 - SGXF90488481 - YRYB
THOMSON MED S$175M4.05%N250128 - SGXF89249654 - RMEB
THOMSON MEDICAL GROUP LIMITED - SG1M49904634 - A50
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Appointment
Date &Time of Broadcast
01-Dec-2021 18:04:24
Status
New
Announcement Sub Title
Appointment of Executive Director
Announcement Reference
SG211201OTHRVP2L
Submitted By (Co./ Ind. Name)
Lim Hoi Leong
Designation
Company Secretary
Description (Please provide a detailed description of the event in the box below)
Appointment of Wan Nadiah binti Wan Mohd Abdullah Yaakob as Executive Director with effect from 1 Jan 2022.

Additional Details

Date Of Appointment
01/01/2022
Name Of Person
Wan Nadiah binti Wan Mohd Abdullah Yaakob
Age
37
Country Of Principal Residence
Malaysia
The Board's comments on this appointment (including rationale, selection criteria, and the search and nomination process)
The Board of Directors of the Company (the Board), having considered the recommendation of the Nominating Committee and having reviewed and considered Ms. Nadiah's qualifications and work experience, are of the view that Ms. Nadiah possesses the requisite experience and capabilities to assume the responsibilities of an Executive Director of the Company. Accordingly, the Nominating Committee recommended, and the Board has approved, the appointment of Ms. Nadiah as an Executive Director of the Company.
Whether appointment is executive, and if so, the area of responsibility
The appointment is an executive position. Ms. Nadiah will be responsible for the overall strategic planning and business growth of TMC Life Sciences Bhd.
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Executive Director
Professional qualifications
MSc. Public Health (Nutrition) from The London School of Hygiene & Tropical Medicine
AB cum laude, Biochemical Sciences from Harvard College
Mandatory Accreditation Programme from The ICLIF Leadership and Governance Centre
J&J Hospital Management Programme from Singapore Management University
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/ or substantial shareholder of the listed issuer or any of its principal subsidiaries
No
Conflict of interests (including any competing business)
No
Working experience and occupation(s) during the past 10 years
2019 to Present
Executive Director & Group Chief Executive Officer
TMC Life Sciences Berhad

2017 to Present
Chief Executive Officer
Thomson Hospital Kota Damansara

2017 to 2019
Group Chief Corporate Officer
TMC Life Sciences Berhad

2016 to 2017
Chief Operating Officer, Clinical Services
Sunway Medical Centre

2012 to 2017
Director, Business Development and Corporate Communications
Sunway Medical Centre
Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6))
Yes
Shareholding interest in the listed issuer and its subsidiaries?
No
# These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8).
Past (for the last 5 years)
See attached
Present
See attached
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?
No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?
No
(c) Whether there is any unsatisfied judgment against him?
No
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?
No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?
No
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?
No
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?
No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?
No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?
No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or
No
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or
No
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or
No
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?
No
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?
No
Any prior experience as a director of an issuer listed on the Exchange?
No
If no, please state if the director has attended or will be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange
Ms Nadiah will be briefed on the duties and roles of a director in a listed company upon her appointment. She will also be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange.

Attachments

Appx 7.4.1_Nadiah directorship.pdf
Total size =188K